ESR1 and breast cancer: These results are consistent with studies that demonstrated the correlation between high-CXCL9 expression and better outcome in patients with whole breast cancer (Razis et al., 2020), the ER-negative cohort (Liang et al., 2021), and the TNBC subtype (Lv et al., 2021).